After Disappointing Results on Phase 3 Trial of Meniere’s Drug, Otonomy Lays off Staff, Suspends Further Trials in 2017
SAN DIEGO, CALIFORNIA — Following disappointing AVERTS-1 Phase 3 trial results of OTIVIDEX in Ménière’s disease patients, Otonomy, Inc., a US-based biopharmaceutical firm, announced that the company is laying off one-third of its noncommercial staff and will not initiate any further clinical trials through the end of 2017. With the announcement, the timing for initiation…
Read More
Otonomy Enrolling Patients in Phase 2 Clinical Trial of OTO-104, to Prevent Cisplatin-Induced Hearing Loss
SAN DIEGO, CALIFORNIA — Otonomy, Inc., a US-based biopharmaceutical firm, announced the enrollment of its first patients in a Phase 2 clinical trial evaluating OTO-104 for prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents, such as cisplatin. This multicenter trial is designed to evaluate the feasibility, safety and efficacy of OTO-104,…
Read More
FDA Fast Tracks Tinnitus Drug; Meniere’s Drug Completes Year-Long Safety Trial
ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced late last month that the US Food and Drug Administration (FDA) granted Fast Track designation to its investigational drug, KeyzilenTM (AM-101). Keyzilen is esketamine gel for intratympanic injection, intended for acute peripheral tinnitus following cochlear injury or otitis media in adults. The Fast Track designation by the FDA of an…
Read More